Can a blood test help avoid unnecessary radiation side effects in rectal cancer?
Part of Cancer, Digestive system clinical trials.
This trial studies if a simple blood test can identify rectal cancers that won't respond well to radiation, so you can avoid unnecessary side effects. You'll give a blood sample before you start radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with rectal adenocarcinoma (a type of rectal cancer confirmed by biopsy).
- You are scheduled to receive chemotherapy and radiation before surgery (neoadjuvant chemoradiation).
- You must be able to understand Dutch or be mentally capable of giving consent.
- You cannot be on a different treatment plan that includes only chemotherapy or short-course radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
This study looks at how well rectal cancer responds to chemotherapy and radiation before surgery. It uses a genetic test on tumor tissue to predict whether the treatment will work for you.
This trial tests whether checking for tumor DNA in your blood after surgery can help decide if you need additional chemotherapy. If the test finds cancer DNA, you may get chemo to lower the risk of the cancer coming back.
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
This trial uses a blood test (liquid biopsy) to look for tiny bits of cancer DNA remaining after surgery. It aims to see if this test can help guide follow-up and treatment decisions for people with colorectal cancer.
Hear when a new Pathological Response Rate, Circulating Tumour DNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.